Cargando…
Consequence of the tumor-associated conversion to cyclin D1b
Clinical evidence suggests that cyclin D1b, a variant of cyclin D1, is associated with tumor progression and poor outcome. However, the underlying molecular basis was unknown. Here, novel models were created to generate a genetic switch from cyclin D1 to cyclin D1b. Extensive analyses uncovered over...
Autores principales: | Augello, Michael A, Berman-Booty, Lisa D, Carr, Richard, Yoshida, Akihiro, Dean, Jeffry L, Schiewer, Matthew J, Feng, Felix Y, Tomlins, Scott A, Gao, Erhe, Koch, Walter J, Benovic, Jeffrey L, Diehl, John Alan, Knudsen, Karen E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492821/ https://www.ncbi.nlm.nih.gov/pubmed/25787974 http://dx.doi.org/10.15252/emmm.201404242 |
Ejemplares similares
-
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer
por: Schiewer, Matthew J., et al.
Publicado: (2008) -
Pepducin-mediated cardioprotection via β-arrestin-biased β2-adrenergic receptor-specific signaling
por: Grisanti, Laurel A., et al.
Publicado: (2018) -
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
por: Schiewer, Matthew J, et al.
Publicado: (2012) -
AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy
por: Schiewer, Matthew J, et al.
Publicado: (2014) -
Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3
por: Yoshida, Akihiro, et al.
Publicado: (2020)